Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone
Authors:
- Kazuyoshi KurashimaKKKazuyoshi Kurashima
- Kenichirou HaraKHKenichirou Hara
- Kouichirou YonedaKYKouichirou Yoneda
- Tetsu KanauchiTKTetsu Kanauchi
- Naho KagiyamaNKNaho Kagiyama
- Daido TokunagaDTDaido Tokunaga
- Noboru TakayanagiNTNoboru Takayanagi
- Mikio UbukataMUMikio Ubukata
- Yutaka SugitaYSYutaka Sugita
- 25 February 2009
- journal article
- research article
- Published by Wiley in Respirology
- Vol. 14 (2) , 239-244
Abstract
Background and objective: The effects of tiotropium, a long‐acting anticholinergic drug, were compared with those of the combination of salmeterol, a long‐acting β2‐agonist, and fluticasone, an inhaled corticosteroid, in patients with COPD.Methods: A 4‐month, randomized, open cross‐over study of tiotropium, 18 µg once daily, versus salmeterol, 50 µg, plus fluticasone, 200 µg, twice daily, was conducted in patients with COPD. Efficacy was assessed by spirometry and responses to the St George's Respiratory Questionnaire (SGRQ). After 4 months, patients were asked to select their subsequent therapy and indicate the reasons for their selection.Results: A total of 78 patients completed the study. There were no significant differences in the improvements in FEV1or SGRQ scores between the therapies. Similar numbers of patients selected tiotropium (42.3%) and salmeterol plus fluticasone (57.7%). However, those who preferred one of the therapies demonstrated greater improvements in SGRQ scores with that therapy. One subgroup of patients (30.8%) showed greater improvements in dyspnoea and FEV1in response to tiotropium, and the other subgroup of patients (35.9%) showed greater improvements in dyspnoea and FEV1in response to salmeterol plus fluticasone. Some patients (14.1%) selected salmeterol plus fluticasone because of positive effects on sputum expectoration.Conclusions: The study was unblinded and the results need to be interpreted with caution. However, tiotropium and salmeterol plus fluticasone had similar overall effects on pulmonary function and SGRQ scores in patients with COPD. Responses to the two therapies were heterogeneous, and the patients who showed greater improvements in FEV1or SGRQ scores with one of the therapies preferred it for their subsequent treatment.Keywords
This publication has 28 references indexed in Scilit:
- The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium BromideAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysisThorax, 2006
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator ResponsesChest, 2003
- Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax, 2003
- Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2002
- A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or SalmeterolChest, 2002
- Tiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung diseaseLife Sciences, 1999
- Role of the Parasympathetic System in Airway Obstruction Due to EmphysemaNew England Journal of Medicine, 1984